Ralph V. Boccia, MD: We always have to consider all the potential comorbidities that patients have when we try to target the specific therapy that would be best for them. With abiraterone, as I mentioned to you, you must use an additional steroid, hydrocortisone. When you use androgen blockade, you can potentially decrease corticosteroid synthesis, and you have the potential to cause adrenal crisis in those patients. We always give additional corticosteroids in patients now who are given abiraterone. The patient who we’re talking about has diabetes, so anytime we give a corticosteroid to a diabetic patient, the gluconeogenesis that occurs can often cause havoc with controlling the patient’s blood sugar. This would not be the best patient to go ahead and give abiraterone to with his androgen deprivation therapy. I’d much rather give either enzalutamide or apalutamide rather than abiraterone.
We like to risk stratify our patients with almost any disease. Whether we’re using monotherapies or multiagent chemotherapies, they’re often going to be defined by what our goal is for that particular patient, the volume of disease they have, and the outcomes and goals we’re looking for, just as we talked about earlier. This is a man with high-volume disease. If we use single-agent monotherapy with androgen deprivation therapy, I quoted you the data, this patient has a short progression-free survival, and then we’ll be on to other things anyway. We want to look at the data for the other clinical trials and see whether we can get around some of those short progression-free survival and potential overall survival issues that we’ve already talked about.
Transcript edited for clarity.
Case: A 66-Year-Old Male with Metastatic Castrate-Sensitive Prostate Cancer
Initial presentation
Clinical Workup
Treatment and Follow-Up
Capivasertib Improves PFS in PTEN-Deficient mHSPC
November 30th 2024Data from the phase 3 CAPItello-281 trial showed that capivasertib plus abiraterone and androgen deprivation therapy significantly improved radiographic progression-free survival in patients with PTEN-deficient metastatic hormone-sensitive prostate cancer.
Read More